Toll-like receptor agonists in cancer therapy

被引：194

作者：

Adams, Sylvia ^{[1
]}

机构：

[1] NYU, Inst Canc, New York, NY 10016 USA

来源：

IMMUNOTHERAPY | 2009年 / 1卷 / 06期

关键词：

bacillus Calmette-Guerin; CpG; imiquimod; immunotherapy; monophosphoryl lipid A; polyriboinosinic-polyribocytidylic acid; resiquimod; Toll-like receptor; Toll-like receptor agonist; vaccine adjuvant; PHASE-I TRIAL; IMIQUIMOD 5-PERCENT CREAM; BACILLUS-CALMETTE-GUERIN; T-CELL RESPONSES; POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID; ACTIVE SPECIFIC IMMUNOTHERAPY; ENHANCES TUMOR RESPONSE; DENDRITIC CELLS; IMMUNE-RESPONSE; CPG OLIGODEOXYNUCLEOTIDES;

D O I：

10.2217/IMT.09.70

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Toll-like receptors (TLRs) are pattern-recognition receptors related to the Drosophila Toll protein. TLR activation alerts the immune system to microbial products and initiates innate and adaptive immune responses. The naturally powerful immunostimulatory property of TLR agonists can be exploited for active immunotherapy against cancer. Antitumor activity has been demonstrated in several cancers, and TLR agonists are now undergoing extensive clinical investigation. This review discusses recent advances in the field and highlights potential opportunities for the clinical development of TLR agonists as single agent immunomodulators, vaccine adjuvants and in combination with conventional cancer therapies.

引用

页码：949 / 964

页数：16

共 160 条

[1] Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant [J].

Adams, Sylvia ;

O'Neill, David W. ;

Nonaka, Daisuke ;

Hardin, Elizabeth ;

Chiriboga, Luis ;

Siu, Kimberly ;

Cruz, Crystal M. ;

Angiulli, Angelica ;

Angiulli, Francesca ;

Ritter, Erika ;

Holman, Rose Marie ;

Shapiro, Richard L. ;

Berman, Russell S. ;

Berner, Natalie ;

Shao, Yongzhao ;

Manches, Olivier ;

Pan, Linda ;

Venhaus, Ralph R. ;

Hoffman, Eric W. ;

Jungbluth, Achim ;

Gnjatic, Sacha ;

Old, Lloyd ;

Pavlick, Anna C. ;

Bhardwaj, Nina .

JOURNAL OF IMMUNOLOGY, 2008, 181 (01) :776-784

[2] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[3] FOXP3 regulates TLR10 expression in human T regulatory cells [J].

Bell, Michael P. ;

Svingen, Phyllis A. ;

Rahman, Meher K. ;

Xiong, Yuning ;

Faubion, William A., Jr. .

JOURNAL OF IMMUNOLOGY, 2007, 179 (03) :1893-1900

[4] A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells [J].

Bernasconi, NL ;

Onai, N ;

Lanzavecchia, A .

BLOOD, 2003, 101 (11) :4500-4504

[5] Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma [J].

Bong, AB ;

Bonnekoh, B ;

Franke, I ;

Schön, MP ;

Ulrich, J ;

Gollnick, H .

DERMATOLOGY, 2002, 205 (02) :135-138

[6] GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development [J].

Brichard, Vincent G. ;

Lejeune, Diane .

VACCINE, 2007, 25 :B61-B71

[7] Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy [J].

Broomfield, Steve A. ;

van der Most, Robbert G. ;

Prosser, Amy C. ;

Mahendran, Sathish ;

Tovey, Michael G. ;

Smyth, Mark J. ;

Robinson, Bruce W. S. ;

Currie, Andrew J. .

JOURNAL OF IMMUNOLOGY, 2009, 182 (09) :5217-5224

[8] Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer [J].

Bruno, S ;

Machi, AM ;

Semino, C ;

Meta, M ;

Ponte, M ;

Varaldo, M ;

Curotto, A ;

Ferlazzo, G ;

Decensi, A ;

Melioli, G .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (01) :47-54

[9] A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) [J].

Butowski, Nicholas ;

Chang, Susan M. ;

Junck, Larry ;

DeAngelis, Lisa M. ;

Abrey, Lauren ;

Fink, Karen ;

Cloughesy, Tim ;

Lamborn, Kathleen R. ;

Salazar, Andres M. ;

Prados, Michael D. .

JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (02) :175-182

[10] A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas [J].

Butowski, Nicholas ;

Lamborn, Kathleen R. ;

Lee, Bee L. ;

Prados, Michael D. ;

Cloughesy, Timothy ;

DeAngelis, Lisa M. ;

Abrey, Lauren ;

Fink, Karen ;

Lieberman, Frank ;

Mehta, Minesh ;

Robins, H. Ian ;

Junck, Larry ;

Salazar, Andres M. ;

Chang, Susan M. .

JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (02) :183-189

← 1 2 3 4 5 6 7 8 9 10 →